CARBARYL 4L INSECTICIDE

SECTION 2: Hazards identification

KEEP OUT OF REACH OF CHILDREN – CAUTION – Harmful if swallowed, inhaled or absorbed through the skin. Avoid breathing of spray mist. Avoid contact with skin, eyes, or clothing. Wash thoroughly with soap and water after handling. Remove contaminated clothing and wash clothing before reuse. This product is white to beige opaque liquid with mild odor. Immediate Effects Eye Causes redness, irritation, tearing. Skin Harmful if absorbed through skin. May produce symptoms similar to those from ingestion. Ingestion: The product causes reversible cholinesterase inhibition. Repeated overexposure may cause more severe cholinesterase inhibition with more pronounce signs and symptoms, May lead to rapid onset of nausea, vomiting, diarrhea, abdominal pain, involuntary shaking, excess salivation, pinpoint pupils, blurred vision, profuse sweating, temporary paralysis, respiratory depression, and convulsions. Inhalation: Harmful if inhaled. May produce symptoms similar to those from ingestion. Medical Conditions Aggravated by Exposure: Inhalation of product may aggravate existing chronic respiratory problems such as asthma, emphysema or bronchitis. Skin contact may aggravate existing skin disease. Warning Statements: NOTE TO PHYSICIAN: This product is a carbamate (cholinesterase-inhibiting) insecticide. Overexposure to this substance may cause toxic signs and symptoms dues to stimulation of the cholinergic nervous system. These effects of overexposure are spontaneously and rapidly reversible. All treatment should be based on observed signs and symptoms of distress in the patient. Consideration should be given to the possibility that overexposure to materials other than this product may have occurred. Specific treatment consists of parenteral atropine sulfate. Improve tissue oxygenation as much as possible before administering atropine to minimize the risk of ventricular fibrillation. Mild case may be given 1 to 2 mg intramuscularly every 30 to 60 minutes until full atropinization has been achieved and repeated thereafter whenever symptoms reappear. Severe cases should be given 2 to 4 mg intramuscularly every 30 to 60 minutes as needed to maintain the effect for at least 12 hours. Dosages for children should be appropriately reduced. Complete recovery from overexposure is to be expected within 24 hours. Persons regularly exposed in manufacturing and handling this product should have a pre-exposure and periodic RBC (red blood cell) cholinesterase level checks.